Skip to main content

Refractory Infantile Spasms clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

    open to eligible people ages 6 months to 36 months

    This open label, multicenter study allows JBPOS0101 (investigational product) to be given as either add-on therapy or monotherapy for patients with refractory infantile spasms. The design and choice of study population of this Phase 2 clinical study is based on the need to provide initial safety, tolerability, pharmacokinetics (PK), and efficacy outcomes of the investigational product for future clinical studies.

    at UCLA UCSF

Last updated: